Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
about
Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestanePoly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane.Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerImpact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy VolunteersThe use of raloxifene in osteoporosis treatment.Role of the UGT2B17 deletion in exemestane pharmacogenetics.Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
P2860
Q33777957-23FCEE48-62BD-43E9-8CB0-FA9DB750DE65Q33777963-0C04E395-4886-4D6C-80B9-40CD279BB537Q34630736-BA7B73B9-A8B1-41F2-B543-C6607BD7B9A6Q34793489-A91B9FB0-9B7F-44AD-B41D-FB7ACCA96E7DQ36508067-C9DD2A87-1F0E-45BA-ADC8-F304A1483586Q36940755-0C60E386-FE30-405B-BE9B-0AD2B6129575Q38092136-784AE1A8-472E-411F-A566-01E745A3C161Q38769425-7B34CA3E-3566-4B50-A0EF-4E58C97E48D0Q41630307-769E39D0-5306-430A-B06B-4DAD2537F3BA
P2860
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@en
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@nl
type
label
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@en
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@nl
prefLabel
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@en
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@nl
P2093
P2860
P50
P1476
Pharmacokinetics and tolerabil ...... th a history of breast cancer.
@en
P2093
B A Duncan
K Panageas
M N Dickler
P2860
P2888
P304
P356
10.1007/S10549-007-9787-1
P407
P577
2007-10-20T00:00:00Z